Last reviewed · How we verify
GH2616 Tablets
At a glance
| Generic name | GH2616 Tablets |
|---|---|
| Sponsor | Suzhou Genhouse Bio Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor. (PHASE1)
- A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GH2616 Tablets CI brief — competitive landscape report
- GH2616 Tablets updates RSS · CI watch RSS
- Suzhou Genhouse Bio Co., Ltd. portfolio CI